Compare
Seres Therapeutics, Inc. vs Monopar Therapeutics vs Prelude Therapeutics Inc vs Silence Therapeutics plc
| Latest fiscal year | Seres Therapeutics, Inc. MCRBRevenue covers only part of its income (partial revenue) | Monopar Therapeutics MNPR | Prelude Therapeutics Inc PRLD | Silence Therapeutics plc SLN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $12.14M | $559.0K |
| Revenue growth (YoY) | n/a | n/a | +73.4% | -98.7% |
| Gross margin | n/a | n/a | n/a | 61.5% |
| Operating margin | n/a | n/a | -861.3% | n/m |
| Net margin | n/a | n/a | -819.6% | n/m |
| Net income | $5.70M | -$13.72M | -$99.50M | -$88.61M |
| EPS (Diluted) | $0.64 | n/a | -$1.29 | -$0.63 |
| Operating cash flow | $1.12M | -$12.20M | -$56.30M | -$62.27M |
| Free cash flow | $865.0K | n/a | -$56.37M | -$62.33M |
| Cash & equivalents | $45.77M | $61.83M | $35.26M | $11.28M |
| Total assets | $138.19M | $140.72M | $141.31M | $131.44M |
| Total liabilities | $93.97M | $2.89M | $72.68M | $69.14M |
| Shareholders' equity | $44.22M | $137.83M | $68.64M | $62.30M |
| Return on year-end equity | 12.9% | -10.0% | -145.0% | -142.2% |
| Shares outstanding | 9.56M | 6.69M | n/a | 141.70M |
Revenue, most recent five fiscal years
| Fiscal year | Seres Therapeutics, Inc. | Monopar Therapeutics | Prelude Therapeutics Inc | Silence Therapeutics plc |
|---|---|---|---|---|
| Latest | n/a | $0 Ended 2025-12-31 | $12.14M Ended 2025-12-31 | $559.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $0 Ended 2024-12-31 | $7.00M Ended 2024-12-31 | $43.26M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $31.64M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $21.66M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |